Surface Oncology, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
50 Hampshire Street, 8 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2023 - Aug 2, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 679 % -22.5%
Debt-to-equity 64.4 % +25.5%
Return On Equity -112 % -132%
Return On Assets -68 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.8M shares +4.81%
Common Stock, Shares, Outstanding 60.7M shares +9.65%
Entity Public Float 85.4M USD -72.3%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.7M shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 60.7M shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 59.8M USD -8.27%
General and Administrative Expense 26.4M USD +1.32%
Operating Income (Loss) -89.4M USD -47.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -92.5M USD -46.9%
Earnings Per Share, Basic -1.6 USD/shares -24%
Earnings Per Share, Diluted -1.6 USD/shares -24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.8M USD -80.2%
Assets, Current 60.6M USD -62.5%
Property, Plant and Equipment, Net 2.5M USD -51.9%
Operating Lease, Right-of-Use Asset 2.92M USD -88.5%
Other Assets, Noncurrent 0 USD -100%
Assets 66M USD -66%
Accounts Payable, Current 609K USD +25.3%
Employee-related Liabilities, Current 5.35M USD +27.9%
Liabilities, Current 16.8M USD -14.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 16.8M USD -75.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -221K USD +81.1%
Retained Earnings (Accumulated Deficit) -252M USD -57.9%
Stockholders' Equity Attributable to Parent 49.2M USD -60.9%
Liabilities and Equity 66M USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.4M USD +0.54%
Net Cash Provided by (Used in) Financing Activities 77K USD -99.6%
Net Cash Provided by (Used in) Investing Activities 1.43M USD -88.5%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 60.7M shares +9.65%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.9M USD -328%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.75M USD +229%
Deferred Tax Assets, Valuation Allowance 72.2M USD +39%
Deferred Tax Assets, Gross 79.7M USD +32.2%
Operating Lease, Liability 30.5M USD -5.7%
Payments to Acquire Property, Plant, and Equipment 17K USD -51.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91.6M USD -42.8%
Lessee, Operating Lease, Liability, to be Paid 42.9M USD -10.3%
Property, Plant and Equipment, Gross 14M USD +4.32%
Operating Lease, Liability, Current 9.49M USD +65.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.63M USD +4.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.79M USD +7.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.5M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.66M USD +2.22%
Deferred Tax Assets, Operating Loss Carryforwards 30.5M USD +0.72%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.78M USD +2.23%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 318K USD -7.83%
Deferred Tax Assets, Net of Valuation Allowance 7.48M USD -10.1%
Share-based Payment Arrangement, Expense 6.12M USD -21.8%
Interest Expense 5.77M USD +129%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%